PT2205279E - Associação farmacêutica de aliscireno e valsartan - Google Patents

Associação farmacêutica de aliscireno e valsartan Download PDF

Info

Publication number
PT2205279E
PT2205279E PT08835893T PT08835893T PT2205279E PT 2205279 E PT2205279 E PT 2205279E PT 08835893 T PT08835893 T PT 08835893T PT 08835893 T PT08835893 T PT 08835893T PT 2205279 E PT2205279 E PT 2205279E
Authority
PT
Portugal
Prior art keywords
aliskiren
valsartan
minutes
dose combination
fixed dose
Prior art date
Application number
PT08835893T
Other languages
English (en)
Inventor
Dieter Becker
Burkhard Schluetermann
Catherine Curdy
Shoufeng Li
Frederic Gerber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2205279E publication Critical patent/PT2205279E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT08835893T 2007-09-28 2008-09-24 Associação farmacêutica de aliscireno e valsartan PT2205279E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97590507P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
PT2205279E true PT2205279E (pt) 2011-07-11

Family

ID=40394241

Family Applications (1)

Application Number Title Priority Date Filing Date
PT08835893T PT2205279E (pt) 2007-09-28 2008-09-24 Associação farmacêutica de aliscireno e valsartan

Country Status (16)

Country Link
US (1) US20100247645A1 (pt)
EP (1) EP2205279B1 (pt)
JP (1) JP2010540548A (pt)
KR (1) KR20100059912A (pt)
CN (1) CN101808665A (pt)
AT (1) ATE505203T1 (pt)
AU (1) AU2008309059A1 (pt)
BR (1) BRPI0817275A2 (pt)
CA (1) CA2697437A1 (pt)
DE (1) DE602008006243D1 (pt)
ES (1) ES2364538T3 (pt)
MX (1) MX2010003439A (pt)
PL (1) PL2205279T3 (pt)
PT (1) PT2205279E (pt)
RU (1) RU2010116526A (pt)
WO (1) WO2009045796A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525648T3 (es) * 2009-01-28 2014-12-26 Novartis Ag Formulaciones galénicas que comprenden Aliskiren
WO2010107971A1 (en) * 2009-03-20 2010-09-23 Novartis Ag Galenical formulations of a fixed dose combination of valsartan and aliskiren
WO2011116115A1 (en) * 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing
SG174658A1 (en) * 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
RU2671575C2 (ru) 2011-05-10 2018-11-02 Теравида, Инк. Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN102626395B (zh) * 2012-04-19 2014-02-26 海南美兰史克制药有限公司 一种阿利克仑缬沙坦药物组合物脂质体固体制剂
US10376470B2 (en) * 2012-05-01 2019-08-13 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
MX365046B (es) * 2012-05-01 2019-05-17 Althera Life Sciencies Llc Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares.
WO2013166114A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe
CN108697688A (zh) 2016-01-20 2018-10-23 塞拉维达公司 用于治疗多汗症的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
CA2580862A1 (en) * 2004-10-08 2006-04-20 Novartis Ag Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
AU2006227283B2 (en) * 2005-03-22 2010-07-01 Novartis Ag Biomarkers for efficacy of aliskiren as a hypertensive agent
KR20130135994A (ko) * 2005-06-27 2013-12-11 다이이찌 산쿄 가부시키가이샤 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를 함유한 약학 제제

Also Published As

Publication number Publication date
WO2009045796A1 (en) 2009-04-09
EP2205279B1 (en) 2011-04-13
CA2697437A1 (en) 2009-04-09
BRPI0817275A2 (pt) 2015-06-16
AU2008309059A1 (en) 2009-04-09
MX2010003439A (es) 2010-04-21
KR20100059912A (ko) 2010-06-04
ATE505203T1 (de) 2011-04-15
DE602008006243D1 (de) 2011-05-26
RU2010116526A (ru) 2011-11-10
ES2364538T3 (es) 2011-09-06
US20100247645A1 (en) 2010-09-30
EP2205279A1 (en) 2010-07-14
CN101808665A (zh) 2010-08-18
PL2205279T3 (pl) 2011-09-30
JP2010540548A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
MX2010003439A (es) Combinacion farmaceutica de aliskiren y valsartan.
TN2010000135A1 (en) Galenical formulations of organic compounds
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
UA92641C2 (ru) Комбинированная препаративная форма, которая содержит амлодипин и лозартан
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MX2010004323A (es) Formas de dosificacion oral que comprenden acetato de licarbazepina.
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
NZ628513A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
WO2008003050A3 (en) Gallium nitrate formulations
IL187632A (en) 17 – Ethinyl – 17 – Hydroxy – 13 – Methyl – 17,16,15,14,13,12,11,9,8,7 – Dachahydro – 6 h– Cyclopentane [a] Penanthran – 3 – Ilmethyl ester of acetoxy acid Acetic, a pharmaceutical dosage unit containing it and its use in the preparation of a contraceptive
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
SI1589014T1 (sl) Postopek za pripravo derivatov 1,3-dihidro-2h-3-benzazepin-2-ona in uporaba za pripravo ivabradina in farmacevtsko sprejemljivih kislinskih adicijskih soli
JO3239B1 (ar) تركيبات جالينية من مركبات عضوية
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
TN2011000100A1 (en) Galenical formulations of organic compounds
MX2011009846A (es) Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.
TW200833375A (en) Pharmaceutical compositions
PL1817029T3 (pl) Pochodna izoksazolowa do łagodzenia bólu neuropatycznego
MY154883A (en) A combination composition